Benzinga | Apr 21, 2021 06:38AM EDT

Kindred's New IL-31 Antibody Shows Improved Shelf Life In PK Study For Canine Dermatitis

* Kindred Biosciences Inc (NASDAQ: KIN) has announced positive results from the pharmacokinetic study (KIND-039) evaluating a new long-acting interleukin (IL)-31 antibody.

* Results from the study demonstrated that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab, thus allowing for up to three-fold longer intervals between dosing.

* The company expects to initiate the pivotal study for this new molecule by the end of this year.

* The new long-acting IL-31 program is complementary to Kindred's tirnovetmab, an interleukin (IL)-31 targeting antibody currently in pivotal efficacy study for the treatment of atopic dermatitis in dogs.

* Price Action: KIN shares are up 6.2% higher at $5 in premarket trading on the last check Wednesday.